Abstract
The Distribution Agreements in Biopharma report provides comprehensive
understanding and unprecedented access to the distribution partnering
agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why
companies enter distribution deals.
The majority of deals are multicomponent whereby the licensor offers a right
to distribute the resultant product of the research collaboration. There are
also numerous pure distribution deals whereby the products originator takes on
a distribution partner in order to maximize a products presence in the
marketplace.
Understanding the flexibility of a prospective partner' s negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 500 links to online copies of actual distribution
contract documents as submitted to the Securities Exchange Commission by
biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner' s flexibility on a wide range of important issues, many of
which will have a significant impact on each party' s ability to derive value
from the deal.
The initial chapters of this report provide an orientation of distribution
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an analysis of the trends in distribution as
well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of distribution deals. The
chapter includes numerous case studies to enable understanding of both pure
distribution deals and multicomponent deals where distribution forms a part.
Chapter 4 provides a review of the leading distribution deals since 2000.
Deals are listed by headline value, signed by bigpharma, most active
bigpharma, and most active of all biopharma companies. Where the deal has an
agreement contract published at the SEC a link provides online access to the
contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of distribution
contract documents available in the public domain. Each deal title links via
Weblink to an online version of the actual contract document, providing easy
access to each contract document on demand.
Chapter 6 provides a comprehensive listing of all distribution agreement
contracts available in the public domain. Each chapter is organized by A-Z,
stage of development at signing, and therapeutic area. Each deal title links
via Weblink to an online version of the actual contract document, providing
easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends
and activities in distribution dealmaking since 2000. In conclusion, this
report provides everything a prospective dealmaker needs to know about
distribution as an opportunity to participate in the commercialization of
either candidate compounds in development or products already on the market.
View Cart
